Introduction
Vitamin A (retinol) and its natural and synthetic derivatives (retinoids) are of crucial importance in the regulation of numerous physiologic processes, including embryonal morphogenesis, visual response, reproduction, growth, cell dierentiation, and immune function. These compounds have also preventive and therapeutic eects on a variety of human cancers, although their mechanisms of action as anticancer agents are still poorly understood. In particular, retinoids proved to be eective in inhibiting the proliferation of neoplastic cell lines of various origin, either independently of or subsequently to the induction of dierentiation (Smith et al., 1992; Warrell, 1994) . These ®ndings stimulated a number of studies aimed at verifying the ecacy of these drugs in the treatment of human malignancies. The most impressive results in this respect are those relative to the use of all-trans-retinoic acid (ATRA) in the treatment of acute promyelocytic leukemia (Castaigne et al., 1990; Warrell et al., 1991) . More recently, retinoids, alone or in combination with other drugs, were shown to have some activity in other hematological malignancies, including juvenile chronic myeloid leukemia, myelodysplastic syndrome, and cutaneous T-cell lymphoma (Smith et al., 1992; Warrell, 1994) . Nevertheless, only a few studies have so far evaluated the possible use of retinoids in the treatment of lymphoproliferative disorders of B-cell lineage. In particular, the data presently available on the eects of retinoids on the proliferation of normal, activated, or neoplastic B lymphocytes are limited.
To verify the in vitro biologic basis that could support the clinical use of retinoids in the treatment of human Epstein ± Barr virus (EBV)-related B-cell lymphoproliferative disorders, particularly those arising in the context of immune de®ciency, we have recently investigated the eects of retinoids on EBVimmortalized lymphoblastoid B-cell lines (LCLs). These latter share several genotypic, phenotypic, biologic, and virologic characteristics with the cells that give rise to EBV-associated lymphoproliferative disorders of immunosuppressed individuals (Nalesnik et al., 1988; Young et al., 1989) . We have shown that retinoids have a strong antiproliferative eect in vitro on EBV-carrying LCLs of various origin, with 13-cisretinoic acid (RA), 9-cis-RA and ATRA being the most eective compounds (Pomponi et al., 1996) . These compounds, in fact, were active at concentrations as low as 10 78 M. Moreover, under our experimental conditions, retinoid-induced growth arrest in vitro appeared irreversible at drug concentrations (10 76 M) that may be reached in man after oral systemic therapy (Pomponi et al., 1996) . The antiproliferative activity exerted by retinoids on LCLs is a generalized phenomenon usually associated with a progressive G 0 /G 1 accumulation of treated cells (Pomponi et al., 1996) . We also showed that the antiproliferative eects of retinoids are not dependent on the induction of terminal dierentiation of EBVinfected B lymphocytes and are not mediated by a direct modulation of viral latent antigens, such as EBNA-2 and LMP-1, which are crucial for EBVinduced B-cell immortalization (Pomponi et al., 1996) .
The progression through the eukaryotic cell cycle is governed by sequential formation, activation, and subsequent inactivation of a series of cyclin-cyclin dependent kinase (CDK) complexes (Reed, 1992; Pines, 1993; Sherr, 1993) . In mammalian cells, the cyclin E/ CDK2 and cyclins D/CDK4,6 complexes are catalytically active during G 1 phase and rate limiting for cell progression through this period (Sherr, 1993) . Many proteins have been suggested as targets for the dierent cyclins-CDKs (Nigg, 1993) . The retinoblastoma susceptibility gene product (pRb) has been identi®ed as a substrate for the G 1 cyclin/CDK complexes, and accumulating evidence suggests that pRb is critical in the control of the transition from G 1 to S phase. Underphosphorylated pRb inhibits cell cycle progression by forming inactive complexes with the E2F/DP family of transcription factors. pRb and other pRb-like proteins (p130 and p107) are progressively phosphorylated during the cell cycle and become hyperphosphorylated in late G 1 , resulting in the release of E2F/ DP factors and the subsequent transcriptional activation of genes essential for S phase progression (Nevins, 1994) . Three dierent cyclin/CDK complexes are involved in the phosphorylation of pRb: cyclins D/ CDK4,6 regulating G 1 progression and cyclin E/CDK2 and cyclin A/CDK2 controlling G 1 to S transition (Sherr, 1996) . The activity of CDKs is regulated by various mechanisms including association with cyclins, phosphorylation at a threonine residue by the CDKactivating kinase (CAK), dephosphorylation of tyrosine residues by the phosphatase cdc25A and association with a group of inhibitory proteins called CDK inhibitors (CKI) (Morgan, 1995; Sherr and Roberts, 1995) . In the mammalian system, two families of CKIs have been identi®ed. The Ink4 family includes the p15, p16, p18, and p19 proteins which bind to CDK4 and CDK6 and can interfere with cyclin-CDK interactions (Sherr and Roberts, 1995) . The Cip/Kip family include p21, p27, and p57 proteins which bind to and inhibit all G 1 cyclin/CDK complexes. Furthermore, CKIs play key roles in the response of cells to extra-or intracellular growthinhibitory signals, such as the transforming growth factor-b (TGF-b) and other cytokines (Sherr and Roberts, 1995) .
The present study was undertaken to better understand the molecular mechanisms by which retinoids inhibit the proliferation of EBV-immortalized B lymphocytes. In particular, we explored the hypothesis that, in these cells, retinoids may act by interfering with cell cycle progression from G 1 to S phase. To this end, we have investigated retinoid-treated cells for the expression and functional activity of the cyclins, their associated kinases and relative inhibitors that are involved in regulating G 1 progression and G 1 to S transition.
Results

Kinetics of cell cycle changes induced by RA in EBVcarrying LCLs
The eects of 10 76 M 13-cis-RA on cell cycle phase distribution were examined in two LCLs (DAA-3 and HDE-14) over a de®ned time course to investigate the kinetics of retinoid-mediated G 0 /G 1 arrest. As shown in Figure 1 , RA treatment was associated with a time-dependent fall in the percentage of cells in the S phase. Nevertheless, both cell lines showed only a limited increase in G 0 /G 1 cells during the ®rst 3 days of treatment. A signi®cantly higher proportion of G 0 / G 1 cells, apparently at the expense of cells in S phase, was observed only after 7 and 10 days of retinoid treatment for HDE-14 and DAA-3 cells, respectively. These ®ndings are consistent with the results of [ 3 H]-thymidine uptake (data not shown) and indicate that the HDE-14 LCL is relatively more sensitive to the antiproliferative eect of 13-cis-RA than DAA-3 cells.
Eects of RA on the phosphorylation of pRb and p130
Since phosphorylation of pRb and related proteins is a requirement for cell cycle progression through G 1 into S phase, as a ®rst step we analyzed the eects of 13-cis- RA on the phosphorylation of pRb and p130 proteins. Figure 2 demonstrates that the G 0 /G 1 arrest induced by 13-cis-RA treatment (10 76 M for 7 days) was associated with a signi®cant decrease in the level of hyperphosphorylated pRb in both DAA-3 and HDE-14 LCLs. An accumulation of underphosphorylated p130 was also shown in HDE-14 cells whereas retinoid treatment did not signi®cantly modify the level of p130 phosphorylation in DAA-3 cells (Figure 2 ). These ®ndings suggest that retinoids inhibit LCL growth mainly through modi®cation of the pRb phosphorylation status.
Eects of RA treatment on G 1 CDK kinase activity To de®ne the mechanisms by which RA prevents the hyperphosphorylation of pRb, we analysed G 1 CDKs which are known to phosphorylate pRb both in vivo and in vitro. We ®rst measured the eect of 13-cis-RA treatment on CDK2, CDK4, and CDK6 kinase activity. Cell lysates were prepared from asynchronously proliferating cells or cells treated for 7 days with 10 76 M 13-cis-RA and immunoprecipitated with antibodies to speci®c CDKs (see Materials and methods). Immunoprecipitated CDK4 and CDK6 complexes from proliferating HDE-14 LCL showed signi®cant activities toward the GST-Rb substrate, whereas these activities were markedly reduced by 13-cis-RA treatment (Figure 3) . In a similar manner, kinase activities toward the histone H1 substrate were immunoprecipitated by antibodies to CDK2 and cyclin E from HDE-14 cells asynchronously proliferating, treated for 7 days with 10 76 M 13-cis-RA or growtharrested at the G 1 /S boundary by aphidicolin. As shown in Figure 4 , 13-cis-RA treatment was associated with a marked fall in CDK2 and cyclin E-associated kinase activity, which declined to approximately 45% and 25% of control, respectively. These results demonstrate that 13-cis-RA treatment was able to eciently inhibit all of the G 1 CDKs that are predominantly associated with the hyperphosphorylation of pRb.
Eects of RA on the expression of G 1 -associated cyclins, CDKs and CKIs
The eects of RA on the expression of G 1 regulatory proteins were investigated in HDE-14 cells arrested in G 0 /G 1 after treatment with 10 76 M 13-cis-RA for 7 days. Immunoblot analysis of cell extracts showed that RA-treated HDE-14 cells had markedly lower amounts of cyclins D3 and A than asynchronously growing cells exposed to the solvent alone (DMSO) ( Figure 5 ). Although expressed at low levels in asynchronous HDE-14 cells, also cyclin D2 was reduced following 13-cis-RA treatment, whereas no evidence of cyclin D1 expression was obtained. Cyclin E protein levels were only slightly decreased after 13-cis-RA exposure ( Figure 5 ). As an internal control, the analysis was also performed on HDE-14 cells growth-arrested at the G 1 /S boundary by aphidicolin treatment which show high levels of cyclins necessary for S-phase progression ( Figure 5 ). We also investigated whether the inhibitory eect of RA on G 1 kinase activity was related to decreased levels of CDKs. Immunoblot analysis showed that 13-cis-RA treatment caused no changes in the levels of CDK4 and CDK6 proteins ( Figure 5 ). Of note, a strong decline in the active phosphorylated form of CDK2 was detected in HDE-14 and DAA-3 cells exposed to 13-cis-RA, whereas untreated cells showed the expected distribution of the unphosphorylated and phosphorylated forms of CDK2 usually observed in unsynchronized proliferating cells ( Figure 5 and data not shown). In fact, 13-cis-RA-treated cells showed a marked reduction of the faster migrating CDK2 band, which corresponds to the CDK2 form carrying the activating phosphorylation on threonine-160 ( Figure 5 ). Similar ®ndings were observed in ATRA-and 9-cis-RA-treated HDE-14 and DAA-3 cells (not shown).
The analysis of CKI expression levels revealed that the growth arrest induced by 13-cis-RA in HDE-14 and DAA-3 cells was associated with a dramatic upregulation of the p27 Kip1 protein ( Figure 5 and data not shown). Markedly increased levels of p27 Kip1 protein were also observed in HDE-14 and DAA-3 cells exposed to 9-cis-RA and ATRA (not shown). p27 mRNA levels did not change signi®cantly after 7 days of treatment (not shown), indicating that the increase observed at the protein level must be regulated posttranscriptionally. Of note, the levels of p27
Kip1 protein varied as a function of the proliferative rate of LCLs.
In fact, cells irreversibly growth-arrested by treatment with 10 76 M 13-cis-RA displayed an increase in the levels of p27
Kip1 protein that persisted for more than 7 days after drug withdrawal. In contrast, p27
Kip1 showed a progressive reduction to basal levels concomitantly with the recovery of LCL proliferation occurring after removal of RA concentrations (10 78 M) responsible for a reversible growth inhibition (Pomponi et al., 1996 and data not shown). No evidence of p21
Waf1 expression was obtained in both 13-cis-RA-treated and untreated HDE-14 cells ( Figure 5 ). Only the cells growth-arrested at the G 1 /S boundary by aphidicolin showed detectable levels of p21 Waf1 ( Figure 5 ). These ®ndings suggest that p21
Waf1 may be involved in cell cycle block induced by aphidicolin. This compound, in fact, prevents DNA chain elongation by inhibiting DNA polymerase and it is known that p21
Waf1 protein (but not p27 Kip1 or p57 Kip2 ) can bind to proliferating cell nuclear antigen (PCNA) and inhibits the PCNA-dependent DNA synthesis catalyzed by DNA polymerase (Li et al., 1994; Waga et al., 1994) . With regard to the Ink4 family of CKIs, no evidence of p15 and p16 expression was found in HDE 14 cells by the antibody available to us (data not shown).
We next examined RA-induced variations of cyclins D3, E and A, CDK2 and p27
Kip1 at dierent time points over a period of 10 days of 13-cis-RA treatment (10 76 M). Immunoblot analysis showed that, in retinoid-treated HDE-14 cells, the levels of p27 Kip1 protein were clearly elevated at 48 h and the increase progressively continued until day 7 of treatment ( Figure 6 ), when the accumulation of cells in G 0 /G 1 was more pronounced. In contrast, the down-regulation of cyclins D3 and A and the decrease in the active phosphorylated form of CDK2 occurred later ( Figure  6 ). These ®ndings support the hypothesis that the primary eect exerted by 13-cis-RA treatment on LCLs is the increase in p27
Kip1 expression levels. Kip1 levels increase in G 1 CDK complexes immunoprecipitated from RA-treated LCLs
Interaction of p27
Kip1 with G 1 cyclins and CDKs was analysed in detail by immunoprecipitation and subsequent Western blot analysis. As shown in Figure  7 , antibodies to CDK2 and CDK4 immunoprecipitated signi®cantly higher levels of associated p27 Kip1 protein from extracts of 13-cis-RA-treated cells than from extracts of proliferating cells (2.5-fold for CDK2 and 1.5-fold for CDK4). In untreated HDE-14 cells, CDK6 showed high levels of associated p21 Kip1 protein, which slightly increased after 13-cis-RA treatment (Figure 7) . Furthermore, after normalization of cyclin levels with the relative amount of CDK immunoprecipitated in each complex, and reprobing the same blots with antibodies to cyclins D3 and E, we demonstrated that 13-cis-RA induced a strong down regulation of cyclin D3 associated with CDK4 and CDK6 (up to 20% of the controls), but did not aect the amount of cyclin E complexed with CDK2 ( Figure 7 ). These results suggest that p27
Kip1 has an important role in 13-cis-RA-mediated LCL growth arrest. In particular, the inhibition of CDK2 activity appeared to be primarily the result of the increased association of p27 Kip1 with the cyclin E/CDK2 complex. In fact, immunoprecipitation of cyclin E showed that 13-cis-RA-treated HDE 14 cells had higher levels (more than twice) of associated p27 Kip1 protein, whereas p27 Kip1 immunoprecipitation and cyclin E Western blot demonstrated that, in treated cells, all cyclin E was associated with p27 Kip1 (Figure  8 ). To further elucidate the signi®cance of RA-induced p27 Kip1 , we studied the time course eect of 13-cis-RA on CDK-bound p27 Kip1 ( Figure 9 ). To this end, CDK2, CDK4 and CDK6 were immunoprecipitated at dierent time points over a period of 7 days of 13-cis-RA treatment. Western blot analysis showed that levels of p27
Kip1 precipitated with anti-CDK2 antibody increased gradually, with a time course similar to that of p27
Kip1 protein induction (Figure 9 ). Moreover, while the amount of p27
Kip1 protein precipitated with anti-CDK6 antibody did not change, the levels of p27
Kip1 associated with CDK4 increased to saturation levels within the ®rst 24 h of RA treatment. These ®ndings suggest that 13-cis-RA-induced p27
Kip1 preferentially binds to CDK2.
LCL growth-arrest induced by 13-cis-RA is not mediated by TGFb
Taking into account that in other systems retinoidinduced antiproliferative eect is mediated by TGFb (Falk et al., 1991) and that G 1 growth arrest induced by this factor is associated with p27
Kip1 up-regulation (Polyak et al., 1994a) , we explored the hypothesis that retinoids inhibit the proliferation of LCLs through the induction of TGFb. To this end, we investigated the Figure 7 Eects of RA on G 1 CDK complexes. Antibodies against the G 1 CDKs were used to immunoprecipitate associated complexes from extracts of proliferating (7) and RA-treated (10 76 M 13-cis-RA for 7 days) (+) HDE-14 cells. The immunoprecipitates were then analysed by immunoblot for the presence of p27
Kip1 and cyclins by serial probing of the same blots with the relevant antibodies. Graphs represent changes in the quantities of cyclins or p27 Kip1 found in the complex relative to the amount of CDK that was immunoprecipitated; the amount found in untreated HDE-14 cell complex was given an arbitrary value of 100% ability of TGFb to block LCL cell growth. The eect of 10 ng/ml recombinant TGFb was examined in HDE-14 LCL and in the TGFb-responsive Burkitt's lymphoma cell line Ramos as a positive control. While TGFb signi®cantly inhibited the [ 3 H]thymidine uptake of Ramos cells, no eect was observed on the proliferation of HDE-14 cells (not shown). Moreover, we also veri®ed whether TGFb1, b2 and b3 neutralizing antibody was able to interfere with the growth inhibitory properties exerted by RA on LCLs. As shown in Figure 10 , HDE-14 cells treated simultaneously with 10 76 M 13-cis-RA and TGFb neutralizing antibody showed the same pattern of [ 3 H]thymidine incorporation displayed by cells exposed to 13-cis-RA alone. Conversely, treatment of Ramos cells with TGFb neutralizing antibody signi®cantly reduced the antiproliferative activity of TGFb. These results seem to rule out that LCL growth arrest induced by retinoids could be mediated by the induction of a TGFb autocrine negative loop.
Discussion
In the present study, we established that the G 0 /G 1 growth arrest induced by RA on EBV-immortalized B lymphocytes is mediated by multiple eects on G 1 regulatory proteins. In fact, RA treatment of LCLs results in the inhibition of the activity of all three G 1 CDKs (CDK2, CDK4 and CDK6) and this correlates with the accumulation of hypophosphorylated forms of endogenous pRb. Since each of the G 1 CDKs has been shown to phosphorylate pRb, inhibition of these kinases induced by RA may account for the accumulation of underphosphorylated pRb and the subsequent G 1 arrest of LCLs. Considering that the antiproliferative eect of RA on LCLs is a generalized phenomenon (Pomponi et al., 1996) , our ®nding that RA was able to signi®cantly modify the level of p130 phosphorylation in some but not in all LCLs suggests that RA inhibits the growth of these cells mainly through modi®cation of the pRb phosphorylation status.
The results presented herein indicate that upregulation of the CDK inhibitor p27
Kip1 is the ®rst relevant change in G 1 regulatory proteins detectable after LCL exposure to RA. Of note, RA treatment increased the levels of p27
Kip1 over a time course that correlated with the previously reported RA-induced /cyclin E association was analysed by immunoprecipitation and immunoblot from extracts of proliferating (7) and RA-treated (10 76 M 13-cis-RA for 7 days) (+) HDE-14 cells. Graphs represent changes in the quantities of cyclin E or p27
Kip1 found in the complex relative to the amount of p27 Kip1 or cyclin E, respectively, that was immunoprecipitated; the amount found in untreated HDE14 cell complex was given an artibrary value of 100%. The immunoprecipitating antibody is indicated at the top of each graph Figure 9 Time course eect of RA on CDK-bound p27 Kip1 . CDK2, CDK4 and CDK6 immunoprecipitates for 13-cis-RAtreated (10 76 M) HDE-14 cells were analysed at the indicated times by immunoblotting using antibody for p27 Kip1 . Graphs represent changes in the quantities of p27
Kip1 associated with CDK2, CDK4 and CDK6, respectively, over a time course of 7 days. For densitometric analysis, an arbitrary value of 100% was given to the amount of p27
Kip1 found in CDK complexes from HDE-14 cells treated for 7 days with 13-cis-RA decrease in [ 3 H]thymidine incorporation (Pomponi et al., 1996) . Our results also indicate that during the ®rst 48 h of RA treatment, p27
Kip1 rapidly saturated CDK4/ 6-cyclin D complexes, whereas the levels of p27 Kip1 associated with CDK2/cyclin E complexes progressively increased over time with kinetics similar to that of RA-mediated p27
Kip1 protein induction. Moreover, the strong up-regulation of p27
Kip1 observed in RAtreated LCLs correlated with a progressive reduction in the active phosphorylated form of CDK2, suggesting that p27 Kip1 inhibited the capacity of CAK to phosphorylate CDK2 at the Thr-160 residue, a crucial event for the induction of kinase activity (Asiedu et al., 1995; Gu et al., 1992) . These ®ndings suggest that the increase in p27
Kip1 occurring within the ®rst 2 days of RA treatment may initiate kinase inhibition, whereas a subsequent up-regulation of p27
Kip1 is required for complete growth arrest. Therefore, unlike what observed in other systems, RA-induced LCL growth inhibition is apparently not associated with redistribution of p27
Kip1 from CDK4/6 to CDK2 complexes. Similarly to what observed in IFNg-mediated growth arrest of mammary epithelial cells (Harvat et al., 1997) , the p27
Kip1 increase induced by RA in LCLs appears to play a role not only in the inhibition of cyclin E/ CDK2, but also in that of other G 1 complexes such as cyclin D/CDK4. Nevertheless, p27
Kip1 up-regulation does not completely account for the dramatic inhibition of CDK4-and CDK6-associated kinase activity observed after RA treatment. This is not the consequence of the decrease in the relative amount of CDK4 and CDK6 proteins. Our results rather indicate that a signi®cant cyclin D down-regulation and a strong decrease in their levels of association with CDK4 and CDK6 probably contribute to the inhibition of these kinases. Nevertheless, the markedly low levels of cyclin D2 detected in our LCLs, together with the ®nding that aphidicolin-treated LCLs showed enhanced cyclin E/CDK2 kinase activity in spite of a signi®cantly inhibited cyclin D2 expression, suggest that cyclin D2 probably does not play a pivotal role in LCL proliferation, as also indicted by recent ®ndings (Blanchard et al., 1997) . On these grounds, it is likely that the decreased amount of cyclin D3 observed in RA-treated cells is the major responsible for the inhibition of CDK4 and CDK6 kinase activity, whereas the role of cyclin D2 in LCL proliferation deserves further investigation. It is worth considering that cyclin D down-regulation constitutes an important event in the proliferative arrest of lymphoid cells. In fact, it has been recently reported that the G 1 arrest induced in T-cell hybridomas by anti-T-cell receptor antibodies was associated with a rapid reduction of cyclin D3 at both mRNA and protein level that resulted in the consequent inhibition of cyclin D3-associated kinase activity (Miyatake et al., 1995) . Available data, however, do not allow to assess whether cyclin D down-regulation is a direct eect of RA treatment, as observed in breast cancer cell lines (Shao et al., 1995; Zhou et al., 1997) or, alternatively, whether this phenomenon is the result of still unidenti®ed biochemical events induced by p27
Kip1 upregulation. The ®nding that the reduction in cyclin D levels occurred after p27
Kip1 increase and concomitantly with RA-induced proliferative arrest appears to support the latter hypothesis. Nevertheless, further studies are required to elucidate this issue. Induction of LCL growth arrest by RA was also associated with a progressive down-regulation of cyclin A which occurred with a time course similar to that of the accumulation of underphosphorylated forms of pRb. Like other genes expressed during G 1 -S transition, such as cdc2, dihydrofolate reductase, and c-myc, the gene encoding for cyclin A is also transactivated by members of the E2F family, which are under the control of pRb. It is likely that the reduced levels of cyclin A observed in RA-treated LCLs are a consequence of the decreased amount of free E2Fs due to the progressive sequestration of these transcriptional regulators by underphosphorylated pRb.
Our results provide evidence for a central role of p27 Kip1 in the RA-induced inhibition of the G 1 traverse by EBV-immortalized B lymphocytes. These ®ndings extend previous observations indicating that this CKI mediates responses to several growth inhibitory signals, including contact inhibition (Fang et al., 1996) , cAMP (Kato et al., 1994) , TGFb (Polyak et al., 1994a) , anti-EGF receptor antibody (Peng et al., 1996) and IL-2 withdrawal (Nourse et al., 1994) . Moreover, our results are consistent with recent ®ndings demonstrating that p27 Kip1 plays a major role in the G 1 arrest mediated by a number of drugs, including rapamycin (Nourse et al., 1994) , lovastatin (Hengst et al., 1994; Nourse et al., 1994) , staurosporine (Kwon et al., 1996; Schnier et al., 1996) , 1,25-dihydroxyvitamin D 3 (Wang et al., 1996) , IFNg (Harvat et al., 1997) and IFNb (Kuniyasu et al., 1997) . The relevance of p27
Kip1 in RA-mediated LCL growth arrest is also highlighted by the observation that up-regulation of this CKI was induced by all three RA compounds (13-cis-RA, 9-cis-RA, and ATRA) able to eectively inhibit LCL proliferation. Moreover, in RA-treated LCLs, high levels of this CKI persisted for more than a week after drug withdrawal concomitantly with the maintenance of the proliferative block. These ®ndings are in keeping with those demonstrating persistent elevation of p27
Kip1 associated with the irreversible growth arrest induced by IFNg in normal mammary epithelial cells (Harvat et al., 1997) or occurring during neuronal (Kranenburg et al., 1995; Lee et al., 1996) and keratinocyte (Hauser et al., 1997) dierentiation.
Available evidence indicates that, in the large majority of the systems investigated, variations in p27 Kip1 protein abundance are not dependent on modulations of transcriptional control (Alessandrini et al., 1997) . Consistently, also RA-induced p27 Kip1 upregulation in LCLs is probably dependent on posttranscriptional mechanisms, as no change was observed in the p27 Kip1 mRNA levels during RA treatment. At present, however, it is not known whether RA is directly responsible for p27
Kip1 upregulation and, in particular, whether RA is able to increase the translation rate of p27
Kip1 and/or inhibit protein degradation. This constitutes an attractive hypothesis that deserves further investigation.
It has been shown that retinoid-induced antiproliferative eect may be mediated by TGFb (Falk et al., 1991) and that G 1 growth arrest induced by this factor is often associated with p27
Kip1 up-regulation (Hengst et al., 1994; Flùrenes et al., 1996) . Moreover, it has been recently demonstrated that TGFb1-induced growth arrest of LPS-stimulated normal mouse B lymphocytes was associated with p27
Kip1 accumulation, cyclin A down-regulation and inhibition of cyclins E and A-dependent kinase activities . Nevertheless, it is highly unlikely that RA-induced LCL growth arrest is mediated by a pathway directly involving TGFb, as suggested by our ®nding that treatment with TGFb neutralizing antibody did not aect the antiproliferative activity of RA.
Previous studies have shown that the antiproliferative activity exerted by RA in other cellular systems may be associated with a c-myc down-regulation (Westin et al., 1982; Kalemkerian et al., 1994; Seewaldt et al., 1995) and that activation of c-myc triggers a rapid induction of cyclin E/CDK2 kinase activity and degradation of p27 Kip1 (MuÈ ller et al., 1997) . On these grounds, it is possible that c-myc regulation may constitute a key initiating event also in RAmediated LCL growth arrest. This constitutes an attractive hypothesis that deserves a thorough investigation. Studies speci®cally aimed at elucidating this important issue are currently in progress in our laboratory.
In conclusion, our results demonstrate that RA treatment of LCLs is associated with multiple eects on G 1 regulatory proteins, including p27 Kip1 upregulation, decreased levels of cyclins D2, D3 and A, and inhibition of CDK2, CDK4 and CDK6 activities, which ultimately result in reduced pRb protein phosphorylation and G 1 growth arrest. These findings constitute a further step toward the de®nition of the mechanisms responsible for the antiproliferative eects exerted by RA on EBV-immortalized B lymphocytes. Elucidation of this issue appears of relevance not only to improve our knowledge on retinoid biology, but also to assess whether these compounds may be of potential usefulness in the treatment of B-cell disorders.
Material and methods
Cell lines and culture conditions
Establishment and characterization of the human EBVimmortalized LCLs DAA-3 and HDE-14 have been previously described (Pomponi et al., 1996) . Cell lines were grown in RPMI 1640 supplemented with 10% heatinactivated fetal calf serum, 100 U/mL penicillin, 100 mg/ mL streptomycin and 20 mmol/L L-glutamine and maintained in a humidi®ed 5% CO 2 incubator at 378C. ATRA and 9-cis-RA were provided by Roche (Basel, Switzerland). 13-cis-RA was purchased from Sigma Chemical Co. (Milan, Italy). The compounds were dissolved in dimethylsulfoxide (DMSO) at 10 71 M and diluted in the culture medium so that the ®nal concentration of the solvent was 40.01% (v/v). RA was handled under subdued light. The stock solutions were stored at 7208C protected from light and oxygen. In some experiments, cells were synchronized at the G 1 /S boundary by aphidicolin block (with 5 mg/ml for 24 h) (Urbani et al., 1995) .
Cell cycle analysis
The in¯uence of retinoids on cell cycle parameters was investigated by¯ow cytometry after propidium iodide staining. To record a DNA histogram, about 10 6 cells were pelleted, resuspended in 500 ml PBS and ®xed with 1 ml ice-cold ethanol for 25 min. Cells were then extensively washed from ®xative and resuspended for 30 min at room temperature in 1 m 50 mg/ml propidium iodide containing 0.1% sodium citrate, 0.01% Nonidet and 0.01 mg/ml ribonuclease A. Cells were then measured immediately using a FACScan (Becton Dickinson, Mountain View, CA): the excitation wavelength in the cytometer was 488 nm and red (610 nm)¯uorescence was recorded. Data acquisition (10 4 events for each sample) and analysis were performed using CELLFIT software (Becton Dickinson).
Western blotting
Whole cell extracts were prepared by lysing 10 7 cells in a buer containing 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 25 mM NaF, 25 mM bglycerolphosphate, 0.1 mM sodium orthovanadate, 0.1 mM phenylmethylsulfonyl¯uoride, 5 mg/ml leupeptin, 1 mg/ml aprotinin, 0.2% Tryton-X-100 and 0.3% Nonidet P-40 (lysis buer). After 20 min incubation at 08C, the extracts were centrifuged for 30 min at 12 000 r.p.m. at 48C. The protein concentration in the lysate was determined by the Bio-Rad protein assay kit (Bio-Rad Laboratories, Richmond, CA). Aliquots of the supernatant were mixed with 26SDS sample buer (150 mM Tris-30% glycerol-3% SDS-1.5 mg/100 ml bromophenol blue dye-100 mM DTT) and denatured at 1008C for 5 min. Equivalent amounts (40 mg) of protein were separated on 12.5% SDS ± PAGE and transferred onto nitrocellulose membrane (Schleiher and Schuell, Keene, NH). Ponceau S staining was performed to con®rm that equal amounts of total protein were present in all the lines. The membrane was blocked with 0.5% casein in PBS for 1 h at room temperature and incubated with the appropriate antibody overnight at 48C. After three washes with 0.5% casein for 5 min, the membranes were incubated for 1 h at room temperature with an appropriate horseradish peroxidase-linked secondary antibody (1 : 1000). Final washes were performed in 0.5% casein for 15 min, PBS-Tryton X-100 for 5 min (three times) and distilled water for 5 min. Immunolabeled bands were detected with the ECL Western blotting detection system (Amersham).
Antibodies
Antibodies used were: p27 Kip1 (1 : 2500), p21 Cip1 (1 : 500), Cdk2 (1 : 2500), Cdk4 (1 : 250), Rb2 (1 : 1000) from Transduction Laboratories (Lexington, KY); p27
Kip1 (C-19, 1 : 1000), cyclin E (HE12, 1 : 1000), cyclin E (C-19, 1 : 1000), cyclin A (H-432, 1 : 2000), cyclin D2 (C-17, 1 : 1000), cyclin D3 (C-16, 1 : 1000), CDK2 (M2, 1 : 1000), CDK6 (C-21, 1 : 1000), CDK4 (H-22, 1 : 1000), and Rb (IF-8, 1 : 1000) from Santa Cruz Technologies, Inc. (Santa Cruz, CA); and cyclin D3 (Ab-2, 1 : 100) from Calbiochem (Oncogene Research, Cambridge, MA).
Immunoprecipitation and kinase assays
Lysates representing 300 mg of protein were precleared by the addition of protein A-Sepharose beads (CL-4B Pharmacia), followed by rocking at 48C for 1 h. To the precleared lysate, 2 mg of appropriate antibody was added, then rocked at 48C for 1 h. The antibody-associated complex was removed by the addition of protein ASepharose at 48C overnight. Pellets were washed three times with lysis buer and, after removal of as much liquid as possible, were resuspended in SDS ± PAGE sample buer for Western blot analysis. For kinase assays, 150 mg of protein lysate was precleared using 2 ml of normal rabbit serum and protein A-Sepharose CL-4B, and immunoprecipitated as described previously. The immunoprecipitated complexes were removed with protein A-Sepharose, and washed twice with lysis buer and once with kinase buer (20 mM Tris-HCl pH 7.4, 10 mM MgCl 2 , 1 mM DTT). Kinase reactions were carried out on the antibody-protein A complex by adding 50 ml of kinase buer containing 30 mM ATP, 2 mg histone H1 (Boerhinger Mannheim) or 2 mg GST-Rb-C-term (Santa Cruz), and 10 mCi [g-32 P]ATP to each reaction. After incubation for 30 min at 378C, reactions were stopped with addition of 50 ml of 26SDS protein sample buer, boiled for 5 min and loaded onto 10% SDS ± PAGE. After electrophoresis, gels were stained with Coomassie Brilliant Blue, ®xed in 20% methanol/10% acetic acid/10% glycerol, dried without heat, and exposed to Hyper®lm (Amersham, Arlington Heights, IL) for 1 ± 6 h at 7808C. All quantitations were done using a GS-670 Imaging Densitometer and Molecular Analysis/PC software (BioRad).
TGF-b neutralizing antibody assay
LCLs (1610 5 /ml in 10% FCS RPMI 1640) were suspended at a concentration of 1610 5 cell ml in 10% FCS RPMI 1640 and plated into 96-well tissue culture plates (Costar, Cambridge, MA), 100 ml/well. Cells were treated with 25 mg/ml TGFb1, b2, b3 neutralizing antibody (Genzyme, Cambridge, MA) and with 10 75 M 13-cis-RA for 1, 2, 3 and 7 days at 378C in a humidi®ed atmosphere of 5% CO 2 /95% air. Cells were pulsed with 1 mCi of [ 3 H]thymidine (5 Ci/ mmol; Amersham, Arlington Heights, IL) during the last 6 h of culture and harvested onto glass ®ber ®lters; radioactivity was measured by liquid scintillation counting. Triplicate samples were averaged, and the percentage of suppression was calculated from untreated control cells and the respective TGFb antibody/13-cis-RA treated cells.
